Tigatuzumab

Drug Profile

Tigatuzumab

Alternative Names: CS-1008; TRA-8

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company; University of Alabama at Birmingham
  • Developer Daiichi Sankyo Company
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action TRAIL receptor 2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Colorectal cancer; Liver cancer; Lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2017 University of Alabama at Birmingham and Daiichi Sankyo completes a phase II trial for Breast cancer (Combination therapy; Metastatic disease) in the US (NCT01307891)
  • 31 Oct 2013 Discontinued - Phase-I for Lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top